Report Highlights
The global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.
Report Includes
- 17 data tables and 25 additional tables
- Analysis of the global markets for cell therapy biomanufacturing
- Analyses of global market trends, with market revenue data from 2022, estimates for 2023, forecasts for 2024 and projected CAGRs through 2029
- Estimates of the current market size and revenue prospects, along with a market share analysis by product type, application, end user and region
- Facts and figures pertaining to the market dynamics, technological advances, product launches, regulatory scenarios, and the expected impact of macroeconomic factors
- An analysis of patents and emerging technologies
- Overview of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies’ ESG score rankings and their ESG practices
- An analysis of the industry structure, including companies’ market shares, merger and acquisition activity, and venture funding
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., Bristol-Myers Squibb Co., Lonza, Merck KGaA, andBioSenic SA
Report Scope
This report discusses the key trends shaping the global cell therapy biomanufacturing market, exploring factors that drive or hinder growth while providing valuable insights for stakeholders and potential newcomers. It examines R&D investment, heightened competition, and emerging technologies steering market dynamics. Moreover, the report assesses how advancements, product launches, and governmental initiatives impact future market trajectories. It also scrutinizes corporate actions like mergers, acquisitions, and partnerships. Additionally, the report evaluates the efficacy of various strategies in light of evolving technologies, intensifying competition, and shifting consumer demands.
Report Synopsis
Report Metrics | Details | ||||||||
---|---|---|---|---|---|---|---|---|---|
Base year considered | 2023 | ||||||||
Forecast period considered | 2024-2029 | ||||||||
Base year market size | $8.6 billion | ||||||||
Market size forecast | $16.7 billion | ||||||||
Growth rate | CAGR of 11.5% for the forecast period of 2024-2029 | ||||||||
Units considered | $ Billions | ||||||||
Segments covered | Product Type, Application Type, and Region | ||||||||
Regions covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) | ||||||||
Countries covered | China, India, Japan, South Korea, Australia, Singapore, U.S., Canada, Mexico, Germany, U.K., Italy, Russia, Spain, and France | ||||||||
Key Market Drivers |
|
||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Christian Goodwin, MD, MPH, is a resident physician at Duke University. He completed his undergraduate degree at the University of Virginia. He obtained his MPH at the University of Liverpool as a US-UK Fulbright Scholar while serving as a visiting researcher at the Palliative Care Institute Liverpool. He obtained his MD from the University of North Carolina as a Blanchard Scholar. Christian has expertise in health systems innovation, public health research, geriatrics, and psychiatry.
Report Highlights
The global market for cell therapy biomanufacturing should grow from $6.5 billion in 2020 to $10.2 billion by 2025, at compound annual growth rate (CAGR) of 9.4% for the period of 2020-2025.
Report Includes
- 23 tables
- An overview of the global markets for cell therapy biomanufacturing
- Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
- Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
- Detailed description of allogeneic (third party donor cells) and autologous (one's own body cells) forms of cell therapy and analysis of its advantages and limitations
- Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
- Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis
- Company profiles of major players of the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG
Related Reports
Global Automated and Closed Cell Therapy Market
The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.
Biologics Development and Manufacturing Testing: Technologies and Global Markets
The global market for biologics safety testing is estimated to increase from $7.4 billion in 2022 to reach $18.2 billion by 2027, at a compound annual growth rate (CAGR) of 19.9% from 2022 through 2027.
Global Primary Cells Market
The global primary cells market should reach $1.9 billion by 2027 from $1.3 billion in 2022 at a compound annual growth rate (CAGR) of 9.0% for the forecast period of 2022 to 2027.
Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy
The global market for chimeric antigen receptor (CAR) T-cell therapy is estimated to grow from $1.5 billion in 2021 to reach $7.6 billion by 2026, at a compound annual growth rate (CAGR) of 39.1% during 2021-2026.
Recent Reports
RNA Sequencing: Technologies and Global Markets
The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.1% during the forecast period of 2024 to 2029.
Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.
European Life Science Tools and Reagents Market
The European market for life science tools and reagents and COVID-19 diagnostics products was valued at $14.7 billion in 2023. The market is expected to grow from $13.0 billion in 2024 to $15.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 3.4% from 2024 through 2029.
Global Multiomics Market
The global market for multiomics is expected to grow from $2.7 billion in 2024 and is projected to reach $5.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.
Drug Discovery Technologies
The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Drug Discovery Technologies
The global market for drug discovery technologies is expected to grow from $111.9 billion in 2024 and is projected to reach $197.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.0% during the forecast period of 2024 to 2029.
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Electric Vehicles and Fuel Cell Vehicles: Global Markets
The global market for electric vehicles and fuel cell vehicles was valued at $655.9 billion in 2023. The market is expected to grow from $758.0 billion in 2024 to $1.8 trillion by 2029, at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More